Parse Biosciences, a QIAGEN company, unveiled a new product called Evercode™ Whole Transcriptome v4. This product improves single-cell RNA sequencing by offering better scalability, higher sensitivity, and a simpler workflow.
With Evercode v4, researchers can now work with up to five million cells and 384 samples in a single test. This helps in designing larger studies while keeping the sample details clear. The new technology allows researchers to detect more genes per cell, using fewer sequencing reads, which helps reduce costs.
A new magnetic bead-based process replaces the need for centrifugation and boosts cell recovery by up to 75%. This is helpful for working with limited or precious samples, providing more data. The simplified process reduces the time researchers spend handling samples and is designed to be compatible with laboratory automation, making it easier to use for labs with different levels of experience.
Evercode v4 also improves gene detection by eliminating off-target readings. This allows higher sensitivity and better detection of genes, even at lower sequencing depths and lower costs compared to other methods. With better sensitivity, Evercode v4 helps researchers study rare cell types or genes that are expressed at low levels.
The new Evercode v4 chemistry is available across the Evercode product line, including Evercode Fixation, and experiments can be processed through Parse’s GigaLab.
According to Coherent Market Insights, the Biotechnology Market is expected to grow at a CAGR of 12.3% from 2025 to 2032. Currently, the market is at USD 1,034.63 Bn in 2025 and is expected to be around USD 2,330.47 Bn by 2032. Increasing prevalence of chronic diseases, new product launches, and strategies like mergers, acquisitions, and collaboration are expected to drive the global biotechnology market growth over the forecast period.
“Our goal from the beginning was to provide the research community with single cell technology that is scalable, accessible, and high-performing,” said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. “Evercode v4 reflects years of work and direct feedback from customers, delivering a leap forward in cell recovery and sensitivity combined with a simpler workflow.”
Source:
News Room: Parse Biosciences
Company: Parse Biosciences
